• Blueprint prides itself on working with leading private and public companies in all stages of development across therapeutics, medical devices and diagnostics. Here is a sample list of clients we've worked with in the U.S., France, Germany, Switzerland and Australia:
  • Alchemia (ASX:ACL)Oncology company with expertise in carbohydrate chemistry
  • Biota (ASX:BTA) Anti-infective drug company with expertise in respiratory diseases
  • Cerus Corporation (Nasdaq:CERS) Biomedical products company commercializing the INTERCEPT Blood System to enhance blood safety
  • Genetic Technologies (ASX:GTG, Nasdaq:GENE) Genetic testing company specializing in breast cancer diagnostics
  • Neuren Pharmaceuticals (ASX:NEU) Biopharmaceutical company developing drugs for brain injury and neurodegeneration
  • Neurotech (private) Biotechnology company developing therapeutics for chronic retinal diseases
  • Perseis Therapeutics (private) Biopharmaceutical company developing therapies against Trefoil Factors (TFF-1 and TFF-3) and Growth Hormone for breast and other cancers
  • Phylogica (ASX:PYC) Revenue generating Phylomer peptide drug discovery company
  • Sunshine Heart (ASX:SHC) Medical device company developing the C-Pulse Heart Assist System for Class III/ambulatory Class IV (moderate to severe) heart failure
  • Threshold Pharmaceuticals (Nasdaq:THLD) Oncology company focused on the development of novel hypoxia induced cancer therapies